BiotechTube
Tolerance Bio

Tolerance Bio

San Diego, United States· Est.
tolerancebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Tolerance Bio is developing thymus-based therapies to treat immune-mediated diseases by leveraging the organ's central role in establishing immune tolerance. The company has a seasoned leadership team with a proven track record in drug development and company building, including the founder who was instrumental in bringing teplizumab (TZIELD) to market. Backed by a $20.2 million seed round, Tolerance Bio is advancing a preclinical pipeline focused on implanted thymic organoids and has initiated a strategic R&D collaboration with ZipCode Bio. Its ambitious goal is to increase healthspan by fundamentally resetting immune function.

OncologyAutoimmune DiseasesTransplant MedicineImmunodeficiencyAllergy

Technology Platform

Multi-platform approach centered on generating functional iPSC-derived thymic organoids to restore, preserve, and manipulate thymic function for controlling immune tolerance.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The platform addresses a vast, unmet need across multiple multi-billion dollar markets (oncology, autoimmunity, transplant) by targeting the root cause of immune dysfunction.
The 'healthspan' angle aligns with the growing longevity investment thesis.
The experienced leadership team significantly de-risks execution and increases the likelihood of securing future funding and partnerships.

Risk Factors

The science is highly complex and preclinical; generating functional, implantable thymic tissue faces major technical and manufacturing hurdles.
As a cell therapy for immune modulation, clinical development will be long, expensive, and face significant regulatory challenges.
The broad platform strategy risks resource dilution compared to focused indication approaches.

Competitive Landscape

The field of thymus regeneration and immune tolerance is nascent but includes academic groups and a few biotechs exploring thymic epithelial cell (TEC) transplants or thymus organoids. Tolerance Bio's specific iPSC-derived organoid approach and its team's proven drug development expertise may give it a competitive edge. It also competes indirectly with developers of tolerogenic vaccines, regulatory T cell therapies, and other immunomodulators.

More companies in Cell & Gene Therapy →More companies in United States →